2077. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the Health Service Executive maintains any national system for monitoring clinical outcomes, complications, or long-term follow-up in respect of children and adolescents from Ireland who receive gender-related medical treatment abroad under the treatment abroad scheme or any related referral pathway; if so, the governance arrangements fo…
2082. Deputy Ken O'Flynn asked the Minister for Health the current clinical governance framework applying to gender identity healthcare services provided to children and adolescents in Ireland pending completion of the updated national model of care; whether a national dataset, audit framework or outcome monitoring system is currently in place for these services; and the safeguards and oversight mechanisms which oper…
2093. Deputy Ken O'Flynn asked the Minister for Health whether her Department has approved or mandated the establishment of a national dataset for the purposes of planning, governance, oversight and evaluation of gender identity healthcare services provided to children and adolescents within the public health system; if not, whether such a dataset will be introduced; and the timeframe for its implementation. [20261/2…
2094. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives any aggregated national data from the Health Service Executive regarding the number of children and adolescents referred to gender identity services each year; if so, the annual totals for each of the years 2018 to 2025; and if she will make a statement on the matter. [20262/26]
2095. Deputy Ken O'Flynn asked the Minister for Health whether any national clinical audit, patient safety review or governance evaluation has been undertaken since 2020 in respect of gender identity services provided to children and adolescents within the public health system; if so, to provide the dates and scope of such reviews; and if she will make a statement on the matter. [20263/26]
2096. Deputy Ken O'Flynn asked the Minister for Health whether the Department has received the report of the expert group established by the Health Service Executive to consider the implications of the final Cass Review for gender healthcare services in Ireland; if so, the date on which the report was received; and whether she intends to publish the report. [20264/26]
2097. Deputy Ken O'Flynn asked the Minister for Health the formal national clinical governance framework that currently applies to gender identity healthcare services provided to minors pending completion of the updated national model of care; and the specific safeguarding standards required under that framework. [20265/26]
2098. Deputy Ken O'Flynn asked the Minister for Health whether her Department has issued any policy direction, guidance or instruction to the Health Service Executive following publication of the final Cass Review regarding the provision of gender identity healthcare services to children and adolescents in Ireland. [20266/26]
2100. Deputy Ken O'Flynn asked the Minister for Health the formal methodological framework used by her Department when evaluating international clinical guidance prior to incorporation into national healthcare policy; and whether such a methodology was applied in respect of international guidance on gender identity healthcare between 2018 and 2023. [20274/26]
2101. Deputy Ken O'Flynn asked the Minister for Health the date on which the Health Service Executive completed its review of the Cass Review; whether the completed review has been submitted to her Department; the date on which her Department received the document, if applicable; whether she intends to publish the review; and if publication is not intended, the reason the document will not be placed in the public dom…
2102. Deputy Ken O'Flynn asked the Minister for Health the terms of reference issued for the Health Service Executive review of the Cass Review; the names or professional roles of the clinical experts who conducted that review; the governance structure under which the work was undertaken; and whether the review included consideration of safeguarding and clinical risk factors affecting children and adolescents. [20289…
2103. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive review of the Cass Review identified any recommendations relating to safeguarding, diagnostic standards, risk mitigation, or clinical governance in the treatment of children and adolescents presenting with gender incongruence or dysphoria; and whether such recommendations are being incorporated into the developing Model of Car…
2104. Deputy Ken O'Flynn asked the Minister for Health the expected timeline for the completion and publication of the updated Model of Care for gender healthcare services being developed by the Health Service Executive; the stages remaining in that process; and whether the Model of Care will be subject to public or professional consultation before adoption. [20291/26]
2105. Deputy Ken O'Flynn asked the Minister for Health whether the State currently maintains a national dataset recording referrals, diagnoses, treatment pathways, clinical interventions and outcomes for persons receiving gender healthcare services in Ireland; if no such dataset currently exists, when she expects one to be established; and whether the development of such a dataset forms part of the updated Model of C…
2106. Deputy Ken O'Flynn asked the Minister for Health whether the Department of Health or the Health Service Executive conducts periodic clinical audits or outcome evaluations of gender healthcare services delivered within the public health system; if such audits are conducted, the frequency and scope of those audits; and if not, whether such a mechanism will be introduced as part of the new Model of Care. [20293/26…
2107. Deputy Ken O'Flynn asked the Minister for Health the evidence base being relied upon by the Health Service Executive in developing the updated Model of Care for gender healthcare services; whether international clinical reviews, including the Cass Review and equivalent reviews in other jurisdictions, are being formally considered; and how such evidence will inform Irish clinical standards. [20294/26]
2108. Deputy Ken O'Flynn asked the Minister for Health the respective roles of her Department and the Health Service Executive in approving the updated Model of Care for gender healthcare services; whether the final Model of Care will require ministerial approval; and whether the Department retains oversight of safeguarding standards applicable to services for persons under 18. [20295/26]
2109. Deputy Ken O'Flynn asked the Minister for Health the total expenditure incurred by the Primary Care Reimbursement Service on salbutamol nebules dispensed under the General Medical Services Scheme in each month from January 2024 to date in 2026. [20299/26]
2110. Deputy Ken O'Flynn asked the Minister for Health the number of claims submitted for salbutamol nebules or equivalent short-acting bronchodilator nebules under the General Medical Services Scheme, the Drugs Payment Scheme, and the Long-Term Illness Scheme, in each of the years 2024 and 2025. [20300/26]
2111. Deputy Ken O'Flynn asked the Minister for Health the number of claims for salbutamol nebules rejected or unpaid by the Primary Care Reimbursement Service in 2024 and 2025, and the reasons for rejection. [20301/26]
2112. Deputy Ken O'Flynn asked the Minister for Health whether the Department or the HSE issued any clinical or reimbursement guidance to pharmacists relating to salbutamol nebule shortages during 2024 or 2025, and if so to provide the details. [20302/26]
2113. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has analysed prescribing substitution patterns for salbutamol nebules during supply shortages, including increased dispensing of inhalers or alternative bronchodilators. [20303/26]
2114. Deputy Ken O'Flynn asked the Minister for Health whether a national governance framework exists within her Department or the Health Service Executive for the monitoring and management of shortages of essential medicines; the statutory or policy basis for that framework; the units responsible for maintaining national oversight; and if she will make a statement on the matter. [20305/26]
2115. Deputy Ken O'Flynn asked the Minister for Health whether the Department receives regular national reports or aggregated data from the Health Products Regulatory Authority or the Health Service Executive relating to shortages of medicines in the State; the frequency of such reporting; and whether the Department maintains a national register or monitoring system for medicines supply disruptions. [20306/26]
2116. Deputy Ken O'Flynn asked the Minister for Health whether a formal risk-assessment or prioritisation system exists within the Department or the Health Service Executive for identifying medicines considered clinically critical, including respiratory medicines such as salbutamol nebules, where supply disruptions may pose patient safety risks; and if she will outline the governance arrangements for managing such ri…